|
|
|
| Study on the Diagnostic Value of PLGF HMGB1 and MPO Levels in Hypertensive Disorder in pregnancy |
| LI Hui, MEI Xiaoqin, JIAO Shun, et al |
| Jingzhou Hospital Affiliated to Changjiang University / Jingzhou Central Hospital, Hubei Jingzhou 434020, China |
|
|
|
|
Abstract Objective: To explore the diagnostic value of placental growth factor (PLGF),high mobility group protein B1 (HMGB1) and myeloperoxidase (MPO) levels in hypertensive disorder complicating pregnancy. Methods: A total of 112 patients with hypertensive disorder in pregnancy who were treated in our hospital were selected as the observation group,112 healthy pregnant women were selected as the control group,and the differences of serum PLGF,HMGB1,and MPO levels were compared,and the differences of serum PLGF,HMGB1,and MPO levels in patients with different severity and pregnancy outcome in the observation group were analyzed,and the value of PLGF,HMGB1,and MPO in diagnosing severe preeclampsia and adverse pregnancy outcomes were analyzed. Results: Compared with the control group,the serum PLGF of the observation group was (46.63 ± 9.97) pg/mL,which was lower (P<0.05),while HMGB1 and MPO were (60.43±11.41) mmol/L and (14.46±1.38) ng/L,respectively,which was higher (P<0.05).The serum PLGF of patients with severe preeclampsia was (37.12±8.85) pg/mL,which was lower than that of patients with hypertensive disorder in pregnancy and mild preeclampsia (P<0.05),while HMGB1 and MPO were (72.78±9.83) mmoL/L and (16.09±1.40) ng/L,respectively,which were higher than those of patients with hypertensive disorder in pregnancy and mild preeclampsia (P<0.05).The serum PLGF of patients with adverse pregnancy outcome in the observation group was (40.41±8.21) pg/mL,which was lower than those without adverse pregnancy outcome (P<0.05),while HMGB1 and MPO were (69.56±8.97) mmoL/L and (16.12±1.97) ng/L,respectively,which were higher than those without adverse pregnancy outcome (P<0.05).The area under the ROC curve of serum PLGF,HMGB1,MPO diagnosis of severe preeclampsia were 0.723,0.805,0.869,respectively,P<0.05.The area under the ROC curve of serum PLGF,HMGB1,MPO prediction of adverse pregnancy outcomes were 0.797,0.829,0.751,respectively,P<0.05. Conclusion: The decrease of serum PLGF level and the increase of HMGB1 and MPO level in patients with hypertensive disorder in pregnancy have a certain relationship with the severity of the disease and adverse pregnancy outcomes,and have a certain value in predicting severe pre-eclampsia and adverse pregnancy outcomes.
|
|
|
|
|
|
[1] 刘佩琳,马丽丽,高万里.血清PLGF,PAPP-A,β-HCG与妊娠期高血压疾病的相关性及预测不良妊娠结局价值[J].中国计划生育学杂志,2022,30(5):1154-1158.
[2] 张文婷,徐晓英,卢蓉.血清sFlt-1和PlGF联合检测对妊娠期急性脂肪肝病情严重程度和疾病预后的评估价值[J].肝脏,2022,27(8):915-919.
[3] 杨孜,张为远.妊娠期高血压疾病诊治指南(2015)解读[J].中国实用妇科与产科杂志,2015,31(10):886-893.
[4] 吉文丽.血清PP-13,PLGF和SFRP5检测对妊娠期糖尿病不良妊娠结局的诊断价值[J].检验医学与临床,2023,20(1):22-26,31.
[5] 张瑜,周红,孟盼盼.NF-κB,E-selection和PLGF在妊娠期高血压大鼠血清及胎盘中的表达水平及意义[J].中国性科学,2023,20(1):22-26,31.
[6] 朱念念,赵敏,夏闪.妊娠期高血压疾病患者孕晚期血清PLGF,VEGF水平与胎儿生长受限的关系[J].山东医药,2022,62(31):31-34.
[7] Sinkey RG,Battarbee AN,Bello NA,et al.Prevention,diagnosis and management of hypertensive disorders of pregnancy:a comparison of international guidelines[J].Curr Hypertens Rep,2020,22(9):66.
[8] Tita AT,Szychowski JM,Andrews WW.Treatment for mild chronic hypertension during pregnancy[J].Reply N Engl Med,2022,387(7):664.
[9] 汪依毅,郑江红,李勤.妊娠期高血压疾病早期筛查预防在围生期保健中的应用价值分析[J].中国妇幼保健,2022,37(10):1788-1791.
[10] Bernstein SL.New management guidelines for mild hypertension during pregnancy[J].MCN Am Matern Child Nurs,2022,47(6):359.
[11] Magee LA,Smith GN,Bloch C,et al.Guideline No.426:hypertensive disorders of pregnancy:diagnosis,prediction,prevention,and management[J].Obstet Gynaecol Can,2022,44(5):547-571. |
|
|
|
2023, Vol. 29 
